Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | An update of COVID-19 in the hemonc clinical setting in Spain

Paula Rodríguez-Otero • 14 May 2020
COMy Virtual 2020
Multiple Myeloma

Here, Paula Rodríguez-Otero, MD, PhD, University of Navarra, Pamplona, Spain, shares her experience of the impact of COVID-19 in the hematological oncology clinical setting in Spain.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paula Rodríguez-Otero

Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3
4:04
Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3
Paula Rodríguez-Otero • 15 Dec 2023
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial
1:56
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial
Paula Rodríguez-Otero • 15 Dec 2023
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab
1:55
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab
Paula Rodríguez-Otero • 15 Jun 2023
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
1:29
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
Paula Rodríguez-Otero • 15 Jun 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Paula Rodríguez-Otero • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Paula Rodríguez-Otero • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Paula Rodríguez-Otero • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Paula Rodríguez-Otero • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals